Resources and Tools

Harm reduction strategies and tools should be accessible to everyone – regardless of location, time, and/or experience.

Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.

This publication describes the recent trends of drug overdose deaths in the United States (U.S.) and the benefits of adopting harm reduction approaches.

This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.

Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.

Because of naloxone’s ability to reverse opioid overdose and its ease of use, by July 15, 2017, all 50 states and the District of Columbia had passed legislation to improve naloxone access, as one strategy to reduce opioid overdose morbidity and mortality.

To address the infectious disease consequences of the opioid crisis in the U.S., a public workshop titled Integrating Infectious Disease Considerations with Response to the Opioid Epidemic was convened on March 12 and 13, 2018, by the National Academies of Sciences, Engineering, and Medicine.

This ready-to-use training package is designed to provide HIV clinicians (including physicians, dentists, nurses, therapists and social workers, and counselors, specialists, and case managers) with an overview of the challenges and strategies for change in working with individuals living with HIV

This ready-to-use training package is designed to provide HIV clinicians (including physicians, dentists, nurses, therapists and social workers, and counselors, specialists, and case managers) with an overview of the opioid crisis and HIV.

This ready-to-use training package is designed to provide HIV clinicians (including physicians, dentists, nurses, therapists and social workers, and counselors, specialists, and case managers) with a detailed overview of screening patients for at‐risk alcohol and other drug use and conducting a b